T2 Biosystems (NASDAQ:TTOO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note issued on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Trading Down 4.5 %

T2 Biosystems stock opened at $0.33 on Friday. T2 Biosystems has a 12-month low of $0.31 and a 12-month high of $8.38. The firm’s fifty day moving average is $0.75 and its 200 day moving average is $2.81.

Institutional Trading of T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in T2 Biosystems, Inc. (NASDAQ:TTOO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned 9.49% of T2 Biosystems as of its most recent filing with the Securities & Exchange Commission. 23.18% of the stock is owned by hedge funds and other institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.